Telix Pharmaceuticals Property Plant And Equipment Gross Over Time
| TLX Stock | 16.49 1.07 6.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Telix Pharmaceuticals Performance and Telix Pharmaceuticals Correlation. Telix |
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telix Pharmaceuticals. If investors know Telix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.1 | Revenue Per Share 1.991 | Quarterly Revenue Growth 0.581 | Return On Assets 0.0797 | Return On Equity 0.2049 |
The market value of Telix Pharmaceuticals is measured differently than its book value, which is the value of Telix that is recorded on the company's balance sheet. Investors also form their own opinion of Telix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Telix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Telix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Property Plant And Equipment Gross Analysis
Compare Telix Pharmaceuticals and related stocks such as Viracta Therapeutics, Dogwood Therapeutics,, and Viking Therapeutics Property Plant And Equipment Gross Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIRX | 4 M | 74 K | 43 K | 23 K | 42 K | 14 K | 3 K | 20 K | 11 K | 820 K | 273 K | 882 K | 414 K | 464 K | 717.8 K |
| VKTX | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 321 K | 25 K | 1.4 M | 1.1 M | 767.4 K |
| DYAI | 801.8 K | 550 K | 390 K | 504.8 K | 539.9 K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 141.4 K | 134.4 K |
| SRZNW | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 9.4 M | 6.9 M | 11.2 M | 9.3 M |
| VNDA | 1.3 M | 964 K | 2.3 M | 2.2 M | 2.4 M | 4.6 M | 5 M | 5.3 M | 4.4 M | 15 M | 4.1 M | 12.4 M | 11 M | 20.3 M | 21.3 M |
| KTTAW | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 21.5 K | 1.3 M | 244 K | 231.8 K |
| VRAX | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 11.1 K | 1.2 M | 669.9 K |
| VRCA | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 255 K | 2.2 M | 4.9 M | 5.8 M | 6 M | 4.8 M | 4.4 M |
| VRDN | 1.1 M | 1.1 M | 1.1 M | 928 K | 1.2 M | 1.2 M | 1.2 M | 563 K | 727 K | 523 K | 787 K | 3.8 M | 4.9 M | 4.4 M | 4.6 M |
Telix Pharmaceuticals and related stocks such as Viracta Therapeutics, Dogwood Therapeutics,, and Viking Therapeutics Property Plant And Equipment Gross description
My Equities
My Current Equities and Potential Positions
| Telix Pharmaceuticals Limited | TLX |
Specialization | Healthcare, Biotechnology |
| Location | Australia |
| Exchange | NASDAQ Exchange |
null 16.49
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.